Variables | SCE patients (n = 42) | Non-SCE patients (n = 58) | P value |
---|---|---|---|
Age (years, IQR) | 66 (55–75) | 61 (51–68) | 0.038* |
Male (n, %) | 26 (61.9%) | 34 (58.6%) | 0.741†|
CHA2DS2-VASc score (points, IQR) | 2 (1–3) | 1 (1–3) | 0.002* |
MoCA score | |||
 Baseline (points, IQR) | 26.5 (21.8–28.0) | 26.0 (22.0–27.0) | 0.888* |
 Post procedure (points, IQR) | 26.0 (22.0–28.0) | 26.0 (23.0–28.3) | 0.572* |
 3 months (points, IQR) | 26.0 (24.0–29.3) | 27.5 (24.0–28.3) | 0.743* |
Ablation strategy | |||
 HPSD strategy (n, %) | 22 (52.4%) | 28 (48.3%) | 0.685†|
 Conventional approach (n,%) | 20 (47.6%) | 30 (51.7%) | |
AF classification | |||
 Paroxysmal (n, %) | 19 (45.2%) | 40 (69%) | 0.017†|
 Persistent (n, %) | 23 (54.8%) | 18 (31%) | 0.020†|
Echocardiography | |||
 LAD (mm, mean ± SD) | 39.3 ± 4.9 | 37.4 ± 4.5 | 0.047¶ |
 LVEF (%, IQR) | 66.0 (63.8–71.3) | 66.0 (61.8–71.3) | 0.376* |
Comorbidities | |||
 Hypertension (n, %) | 28 (66.7%) | 19 (32.8%) |  < 0.001†|
 Coronary artery disease (n, %) | 14 (33.3%) | 9 (15.5%) | 0.037†|
 Diabetes mellitus (n, %) | 6 (14.3%) | 7 (12.1%) | 0.745†|
 Heart failure (n, %) | 0 | 4 (7.0%) | 0.137‡ |
 Stroke/TIA (n, %) | 6 (14.3%) | 8 (13.8%) | 0.944†|
 Hyperlipidemia (n, %) | 7 (16.7%) | 17 (29.3%) | 0.144†|
Laboratory test | |||
 Creatinine (mmol/L, IQR) | 71.1 (64.3–85.6) | 70.1 (61.8–86.0) | 0.992* |
 NT-proBNP level (pg/ml, IQR) | 415.3 (123.8–1008.1) | 219.1 (107.0–766.3) | 0.230* |